Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022

被引：1
|
作者：
Benjamin, David J. [1 ,3 ]
Kalebasty, Arash Rezazadeh [2 ]
机构：
[1] Hoag Family Canc Inst, Newport Beach, CA USA
[2] Univ Calif Irvine, Med Ctr, Dept Med, Div Hematol Oncol, Orange, CA USA
[3] Hoag Family Canc Inst, 1 Hoag Dr,Bldg 41, Newport Beach, CA 92663 USA
来源：
CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2024年 / 18卷
关键词：
D O I：
10.1177/11795549241227413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Re: Abiraterone and Increased Survival in Metastatic Prostate Cancer
    Richie, Jerome P.
    [J]. EUROPEAN UROLOGY, 2011, 60 (04) : 871 - 871
  • [32] Local Therapy Improves Survival in Metastatic Prostate Cancer
    Leyh-Bannurah, Sami-Ramzi
    Gazdovich, Stephanie
    Budaeus, Lars
    Zaffuto, Emanuele
    Briganti, Alberto
    Abdollah, Firas
    Montorsi, Francesco
    Schiffmann, Jonas
    Menon, Mani
    Shariat, Shahrokh F.
    Fisch, Margit
    Chun, Felix
    Steuber, Thomas
    Huland, Hartwig
    Graefen, Markus
    Karakiewicz, Pierre I.
    [J]. EUROPEAN UROLOGY, 2017, 72 (01) : 118 - 124
  • [33] Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
    Wang, Xiao-Song
    Shankar, Sunita
    Dhanasekaran, Saravana M.
    Ateeq, Bushra
    Sasaki, Atsuo T.
    Jing, Xiaojun
    Robinson, Daniel
    Cao, Qi
    Prensner, John R.
    Yocum, Anastasia K.
    Wang, Rui
    Fries, Daniel F.
    Han, Bo
    Asangani, Irfan A.
    Cao, Xuhong
    Li, Yong
    Omenn, Gilbert S.
    Pflueger, Dorothee
    Gopalan, Anuradha
    Reuter, Victor E.
    Kahoud, Emily Rose
    Cantley, Lewis C.
    Rubin, Mark A.
    Palanisamy, Nallasivam
    Varambally, Sooryanarayana
    Chinnaiyan, Arul M.
    [J]. CANCER DISCOVERY, 2011, 1 (01) : 35 - 43
  • [34] Characterization of KRAS rearrangements in metastatic prostate cancer
    Wang, Xiao-Song
    Shankar, Sunita
    Dhanasekaran, Saravana M.
    Ateeq, Bushra
    Sasaki, Atsuo T.
    Jing, Xiaojun
    Robinson, Daniel
    Cao, Qi
    Gopalan, Anuradha
    Reuter, Victor E.
    Cantley, Lewis C.
    Rubin, Mark A.
    Palanisamy, Nallasivam
    Varambally, Sooryanarayana
    Chinnaiyan, Arul M.
    [J]. CANCER RESEARCH, 2011, 71
  • [35] Survival benefit of local versus no local treatment for metastatic prostate cancerImpact of baseline PSA and metastatic substages
    Pompe, Raisa S.
    Tilki, Derya
    Preisser, Felix
    Leyh-Bannurah, Sami-Ramzi
    Bandini, Marco
    Marchioni, Michele
    Gild, Philipp
    Tian, Zhe
    Fossati, Nicola
    Cindolo, Luca
    Shariat, Shahrokh F.
    Huland, Hartwig
    Graefen, Markus
    Briganti, Alberto
    Karakiewicz, Pierre I.
    [J]. PROSTATE, 2018, 78 (10): : 753 - 757
  • [36] Re: Association of Bone Metastatic Burden with Survival Benefit from Prostate Radiotherapy in Patients with Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
    Taneja, Samir S.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (01): : 159 - 160
  • [37] A survival benefit from radical prostatectomy for early prostate cancer
    Ray, E
    O'Brien, T
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (10) : 1122 - 1123
  • [38] Drug improves survival of metastatic, castration-resistant prostate cancer by 30% in Phase III trial
    不详
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (02) : 100 - 100
  • [39] Patient expectations of benefit from systemic treatments for metastatic prostate cancer
    Oswald, Laura B.
    Kasimer, Rachel
    Rappazzo, Katherine
    Fought, Angela J.
    Penson, David F.
    Morgans, Alicia K.
    [J]. CANCER MEDICINE, 2020, 9 (03): : 980 - 987
  • [40] Current Data confirms the Benefit of Zytiga® in the Treatment of metastatic Prostate Cancer
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 422 - 422
12345